SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
MINNEAPOLIS, March 11, 2016 -- Skyline Medical Inc. (NASDAQ:SKLN) (the “Company”) today announced that it intends to conduct a registered exchange offer to issue new Series B Warrants of the Company in exchange for its outstanding Series A Warrants.
Each outstanding Series A Warrant currently represents the right to (1) effect a cashless exercise permitting the holder to receive shares of common stock under a formula set forth in the Series A Warrants or (2) purchase one share of common stock for $4.95 per share in a cash exercise. Currently, under the formula for a cashless exercise, each Series A Warrant represents the right to receive approximately 10.1 shares of common stock.
The terms of the Series B Warrants are expected to include the following features:
- The Series B Warrants will permit a cashless exercise at a fixed rate rather than a formula. For each Series A Warrant tendered in the exchange offer, the holder will receive Series B Warrants that entitle the holder to receive 10.2 shares of common stock upon a cashless exercise (subject to adjustment for stock splits, reverse stock splits, etc.).
- The Series B Warrants will expire on December 31, 2020, compared to the expiration date of August 31, 2020 for the Series A Warrants.
- Similar to the Series A Warrants, the Series B Warrants will contain a limitation under which exercise is not permitted to the extent that the holder or its affiliates would beneficially own in excess of 4.99% of the Company’s outstanding common stock.
- Otherwise, the terms of the Series B Warrants are expected to be similar to the terms of the Series A Warrants.
The Company expects to commence the exchange offer following the filing of a Form S-4 registration statement setting forth the terms of the exchange offer.
Important Notice
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Investor and Media Contact: Garth Russell KCSA Strategic Communications 212-896-1250 [email protected]
